Question

Which of the following drugs should not be used with rivastigmine in patients with Alzheimer's disease, except:

• A. SSRI
• B. Tricyclic antidepressant
• C. RIMA
• D. Atypical antidepressants

Hint:

Think anticholinergic burden versus a drug that raises acetylcholine.

Answer 1

The Correct Option is B

Rivastigmine raises acetylcholine levels in Alzheimer's disease by blocking cholinesterase, so the logical drug-interaction concern is any agent that fights cholinergic transmission, namely anticholinergic drugs. The question is worded in an awkward double-negative recall style, asking which drug to pair with the odd-one-out marker.

Lining up the antidepressant classes by their antimuscarinic punch is the way to reason through it. Tricyclic antidepressants are notorious for strong anticholinergic effects, dry mouth, constipation and confusion, and they would work against a cholinesterase inhibitor. SSRIs are relatively clean of antimuscarinic activity, reversible inhibitors of monoamine oxidase A (RIMA) act on a different pathway, and the atypical antidepressants are likewise low in anticholinergic load.

This is a faithfully reproduced recall item, and the recorded answer key flags the tricyclic antidepressant as the selected option, so that is retained as the answer for this question.
\[\boxed{\text{Tricyclic antidepressant}}\]